Nyxoah S.A.

NYXH

NASDAQHealthcareMedical - Specialties

Open in GoAI

Previous close

$1.60

−$0.04 · -2.44%

Aug 21, 4:00 PM ET

Pre-market

$1.65

+$0.05 · +3.12%

Aug 24, 4:00 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

41/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Undervalued

Momentum

Strong Down

Sentiment

Mixed

Risk resilience

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Industry: Medical - Specialties
Sector: Healthcare
Headquarters: BE
CEO: Olivier Taelman
Listed since: Apr 28, 2021
Employees: 154

Market position

Day range

Current $1.60

$1.59$1.66

52-week range

Current $1.60

$1.26$6.875

Open: $1.66
Previous close: $1.64
Volume: 164.07K; 0.77× average
Average volume: 212.29K; Average daily volume
Market cap: 160.12M USD
Beta: 0.95; Market reference 1
50-day average: $1.5658; +2.18% above average
200-day average: $3.3623; -52.41% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 161.26M EUR
P/E (TTM): -0.63×
P/B (TTM): 0.94×
P/S (TTM): 6.06×
EV / EBITDA: -1.95×
Earnings yield: -60.38%
Free cash flow yield: -45.78%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 51.31%
Operating margin: -383.05%
Net margin: -434.72%
Return on equity: -183.43%
Return on assets: -76.07%
Return on invested capital: -88.95%

Financial health

Debt / equity: 0.63×
Current ratio: 1.25×

NYXH news

seekingalpha.comAug 5, 2026

Nyxoah SA (NYXH) Q2 2026 Earnings Call Transcript

Read source

marketbeat.comAug 5, 2026

Nyxoah Q2 Earnings Call Highlights

Nyxoah NASDAQ: NYXH reported second-quarter worldwide net revenue of €7.7 million, up 21% sequentially from the first quarter, as its U.S. commercial launch continued to expand. U.S. net revenue reached €5.2 million, a…

Read source

globenewswire.comAug 5, 2026

Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2…

Read source

globenewswire.comJul 27, 2026

Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026

Nyxoah to Release Second Quarter 2026 Financial Results on August 5, 2026 Mont-Saint-Guibert, Belgium – July 27, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”),…

Read source

marketbeat.comJul 10, 2026

Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day

Nyxoah NASDAQ: NYXH used its investor day presentation to outline early U.S. launch progress for its Genio hypoglossal nerve stimulation system, address reimbursement questions and describe its path toward profitability.

Read source